Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

See more here


Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update

See more here


Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

See more here


Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging

Collaboration to Develop Pharmacodynamic Biomarkers for Buntanetap

See more here


Scripps Health and UT Health San Antonio purchase Oncora’s software to improve physician documentation and enhance personalized cancer care

See more here


Melior Announces Substantial Additions to Its Management and Scientific Team 

• Dr. Ken Kilgore joins Melior as VP of Scientific Operations

• Dr. Hongyan Li joins Melior as Director of Oncology

• Dr. Vivian Cong rises to VP of Research & Development

See more here


WellTrackONE Corporation releases Targeted Risk Adjustment Coding system (TRAC)

TRAC will help with HCC RAF scores, lost revenue opportunities and avoidance of RAC/RADV audit penalties

See more here


Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund

See more here


Immunome Reports Fourth Quarter and Full Year 2021 Financial Results

Immunome Receives Safe-to-Proceed Notification from U.S. FDA for IMM-BCP-01 Investigational New Drug Application 

Immunome Continues to Progress IMM-BCP-01 Towards Phase 1b Clinical Trial 

Ongoing Progress on Oncology Pipeline, Including Lead Program Targeting IL-38, a Novel Innate Immunome Checkpoint –

See more here